Two Sigma Securities, LLC Kazia Therapeutics LTD Transaction History

Two Sigma Securities, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.2 - $0.45 $7,999 - $17,999	-39,999 Reduced 68.46%	18,424 $5,000
Q4 2023 Feb 14, 2024	BUY	$0.39 - $0.99 $22,784 - $57,838	58,423 New	58,423 $25,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.23 $246 - $606	493 Added 4.2%	12,234 $7,000
Q3 2022 Nov 14, 2022	SELL	$1.1 - $4.19 $14,293 - $54,444	-12,994 Reduced 52.53%	11,741 $13,000
Q2 2022 Aug 15, 2022	BUY	$4.1 - $8.38 $101,413 - $207,279	24,735 New	24,735 $104,000

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $87.5M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.